Current and future systemic treatments for renal cell carcinoma.
Systemic treatment of renal cell carcinoma has changed dramatically since 2007, with the development and approval of six new agents, which target complex molecular pathways regulating tumour angiogenesis and cell proliferation and survival. These treatments have significantly improved survival times in metastatic renal cell carcinoma, but remain palliative. A number of newer agents are in clinical development, which offer theoretical advantages over existing treatments, and research methodologies are adapting with the aim of defining an individualised approach to therapy which exploits the underlying tumour biology. This review will provide an overview of current and emerging systemic treatments and how they might be integrated with surgical therapy, with a particular focus on advanced, clear cell metastatic renal cell carcinoma.
Royal Marsden Hospital, London, UK.
Rosalie
R
Fisher
Martin
M
Gore
James
J
Larkin
D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000601:surgery*